{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:40:17Z","timestamp":1783568417670,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03851-y","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T12:00:02Z","timestamp":1740225602000},"page":"3465-3476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6711-8886","authenticated-orcid":false,"given":"Izael Pereira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2054-1978","authenticated-orcid":false,"given":"Lucas Guimar\u00e3es Campos Roriz","family":"de Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8516","authenticated-orcid":false,"given":"Gabriel Vieira","family":"Piredda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-8412","authenticated-orcid":false,"given":"Marcelo","family":"Mass-Lindenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4497-3923","authenticated-orcid":false,"given":"Pedro F. S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-5198","authenticated-orcid":false,"given":"B\u00e1rbara Vieira Lima Aguiar","family":"Mel\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0845-9651","authenticated-orcid":false,"given":"Helisandro Montenegro","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4947-0304","authenticated-orcid":false,"given":"Karine Martins","family":"da Trindade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"1","key":"3851_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin [Internet]. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin [Internet]."},{"issue":"3","key":"3851_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin [Internet]."},{"issue":"4","key":"3851_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3322\/canjclin.22.4.232","volume":"22","author":"C Huggins","year":"1972","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin [Internet]. 1972;22(4):232\u201340. https:\/\/doi.org\/10.3322\/canjclin.22.4.232.","journal-title":"CA Cancer J Clin [Internet]"},{"issue":"8","key":"3851_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/nejmoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med [Internet]. 2015;373(8):737\u201346. https:\/\/doi.org\/10.1056\/nejmoa1503747.","journal-title":"N Engl J Med [Internet]"},{"issue":"21","key":"3851_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med [Internet]. 2011;364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/nejmoa1014618.","journal-title":"N Engl J Med [Internet]."},{"issue":"13","key":"3851_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/nejmoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med [Internet]. 2012;367(13):1187\u201397. https:\/\/doi.org\/10.1056\/nejmoa1207506.","journal-title":"N Engl J Med [Internet]."},{"issue":"2","key":"3851_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol [Internet]. 2015;16(2):152\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(14)71205-7.","journal-title":"Lancet Oncol [Internet]."},{"issue":"5","key":"3851_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/nejmoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med [Internet]. 2014;371(5):424\u201333. https:\/\/doi.org\/10.1056\/nejmoa1405095.","journal-title":"N Engl J Med [Internet]."},{"issue":"4","key":"3851_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1758834014529176","volume":"6","author":"DL Suzman","year":"2014","unstructured":"Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol [Internet]. 2014;6(4):167\u201379. https:\/\/doi.org\/10.1177\/1758834014529176.","journal-title":"Ther Adv Med Oncol [Internet]."},{"issue":"2","key":"3851_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.eururo.2013.08.008","volume":"65","author":"SS Sridhar","year":"2014","unstructured":"Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol [Internet]. 2014;65(2):289\u201399. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.008.","journal-title":"Eur Urol [Internet]."},{"issue":"9747","key":"3851_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(10)61389-x","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet [Internet]. 2010;376(9747):1147\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(10)61389-x.","journal-title":"Lancet [Internet]."},{"key":"3851_CR12","doi-asserted-by":"publisher","unstructured":"van Soest RJ, de Morr\u00e9e ES, Kweldam CF, Wiemer EAC, Mathijssen RHJ, de Wit R, et al. (2016) Reply to Masaki Shiota and Akira yokomizo\u2019s letter to the editor re: Robert J. van Soest, Ellen S. de morr\u00e9e, Charlotte F. kweldam, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur urol, 67:981\u20135. Eur Urol [Internet], 69(3):43\u20134. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.024","DOI":"10.1016\/j.eururo.2015.07.024"},{"issue":"17","key":"3851_CR13","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.ejca.2015.07.037","volume":"51","author":"RJ van Soest","year":"2015","unstructured":"van Soest RJ, Nieuweboer AJM, de Morr\u00e9e ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer [Internet]. 2015;51(17):2562\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.037.","journal-title":"Eur J Cancer [Internet]."},{"issue":"28","key":"3851_CR14","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/jco.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA. J Clin Oncol [Internet]. 2017;35(28):3189\u201397. https:\/\/doi.org\/10.1200\/jco.2016.72.1068.","journal-title":"J Clin Oncol [Internet]."},{"issue":"28","key":"3851_CR15","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/jco.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard A-C, Kim CS, G\u00e9czi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer\u2014PROSELICA. J Clin Oncol [Internet]. 2017;35(28):3198\u2013206. https:\/\/doi.org\/10.1200\/jco.2016.72.1076.","journal-title":"J Clin Oncol [Internet]."},{"issue":"4","key":"3851_CR16","doi-asserted-by":"publisher","first-page":"e0195790","DOI":"10.1371\/journal.pone.0195790","volume":"13","author":"JP Fryzek","year":"2018","unstructured":"Fryzek JP, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, et al. Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One [Internet]. 2018;13(4):e0195790. https:\/\/doi.org\/10.1371\/journal.pone.0195790.","journal-title":"PLoS One [Internet]."},{"key":"3851_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.789319","author":"J Chen","year":"2022","unstructured":"Chen J, Zhang Y, Zhang X, Zhao J, Ni Y, Zhu S, et al. Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: a systematic review and network meta-analysis. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2021.789319.","journal-title":"Front Pharmacol"},{"key":"3851_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ [Internet]"},{"key":"3851_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"3851_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"3851_CR21","doi-asserted-by":"publisher","unstructured":"Page MJ, Higgins JPT, Sterne JAC. Assessing risk of bias due to missing results in a synthesis [Internet]. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. p. 349\u201374. https:\/\/doi.org\/10.1002\/9781119536604.ch13","DOI":"10.1002\/9781119536604.ch13"},{"key":"3851_CR22","doi-asserted-by":"publisher","unstructured":"Chowdhury S, Birtle AJ, Bjartell A, Costa L, Feyerabend S, Galli L, et al. (2017) Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry. J Clin Oncol [Internet]. 35(15_suppl):5028\u20135028. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.5028","DOI":"10.1200\/jco.2017.35.15_suppl.5028"},{"issue":"3","key":"3851_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00120-012-2804-y","volume":"51","author":"MM Heck","year":"2012","unstructured":"Heck MM, H\u00f6ppner M, Horn T, Thalgott M, Gschwend JE, Retz M. Abiraterone- und Cabazitaxel-H\u00e4rtefallprogramm: erste klinische Erfahrungen bei Docetaxel-vorbehandelten kastrationsresistenten Prostatakarzinompatienten. Urologe A [Internet]. 2012;51(3):390\u20137. https:\/\/doi.org\/10.1007\/s00120-012-2804-y.","journal-title":"Urologe A [Internet]."},{"issue":"9","key":"3851_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.12788\/jcso.0072","volume":"12","author":"A Houts","year":"2014","unstructured":"Houts A, Hennessy D, Walker M, Nicacio L, Thompson S, Miller P, et al. Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel. J Community Support Oncol [Internet]. 2014;12(9):321\u20138. https:\/\/doi.org\/10.12788\/jcso.0072.","journal-title":"J Community Support Oncol [Internet]."},{"key":"3851_CR25","doi-asserted-by":"publisher","unstructured":"Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, et al. (2017) Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol [Internet]. https:\/\/doi.org\/10.1007\/s12032-017-1014-2","DOI":"10.1007\/s12032-017-1014-2"},{"key":"3851_CR26","doi-asserted-by":"publisher","unstructured":"Puente J, Gonz\u00e1lez-del-Alba A, Sala-Gonzalez N, M\u00e9ndez-Vidal MJ, Pinto A, Rodr\u00edguez \u00c1, et al. (2019) Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer [Internet]. https:\/\/doi.org\/10.1186\/s12885-019-5974-9","DOI":"10.1186\/s12885-019-5974-9"},{"issue":"4","key":"3851_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clgc.2014.12.019","volume":"13","author":"G Sonpavde","year":"2015","unstructured":"Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer [Internet]. 2015;13(4):309\u201318. https:\/\/doi.org\/10.1016\/j.clgc.2014.12.019.","journal-title":"Clin Genitourin Cancer [Internet]."},{"issue":"26","key":"3851_CR28","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/nejmoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, W\u00fclfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med [Internet]. 2019;381(26):2506\u201318. https:\/\/doi.org\/10.1056\/nejmoa1911206.","journal-title":"N Engl J Med [Internet]."},{"key":"3851_CR29","doi-asserted-by":"publisher","unstructured":"van der Zande K, van der Noort V, Busard M, Hamberg P, Ras - van Spijk S, De Feijter J, et al. First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). J Clin Oncol [Internet]. 2021;39(15):5059\u20135059. https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.5059","DOI":"10.1200\/jco.2021.39.15_suppl.5059"},{"issue":"5_suppl","key":"3851_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1200\/jco.2012.30.5_suppl.17","volume":"30","author":"D Mukherji","year":"2012","unstructured":"Mukherji D, Pezaro CJ, Bianchini D, Zivi A, De Bono JS. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel. J Clin Oncol [Internet]. 2012;30(5_suppl):17\u201317. https:\/\/doi.org\/10.1200\/jco.2012.30.5_suppl.17.","journal-title":"J Clin Oncol [Internet]."},{"issue":"10","key":"3851_CR31","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/1535-7163.mct-17-1269","volume":"17","author":"AP Lombard","year":"2018","unstructured":"Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, et al. Intra versus inter cross-resistance determines treatment sequence between taxane and AR-targeting therapies in advanced prostate cancer. Mol Cancer Ther [Internet]. 2018;17(10):2197\u2013205. https:\/\/doi.org\/10.1158\/1535-7163.mct-17-1269.","journal-title":"Mol Cancer Ther [Internet]."},{"issue":"2","key":"3851_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","volume":"68","author":"N Al Nakouzi","year":"2015","unstructured":"Al Nakouzi N, Le Moulec S, Albig\u00e8s L, Wang C, Beuzeboc P, Gross-Goupil M, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol [Internet]. 2015;68(2):228\u201335. https:\/\/doi.org\/10.1016\/j.eururo.2014.04.015.","journal-title":"Eur Urol [Internet]."},{"issue":"6","key":"3851_CR33","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","volume":"65","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, de Wit R. Taxane mechanisms of action: Potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol [Internet]. 2014;65(6):1198\u2013204. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.022.","journal-title":"Eur Urol [Internet]."},{"issue":"10","key":"3851_CR34","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev [Internet]. 2015;41(10):884\u201392. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.002.","journal-title":"Cancer Treat Rev [Internet]."},{"key":"3851_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9511","author":"A Romanel","year":"2015","unstructured":"Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma\u00a0AR\u00a0and abiraterone-resistant prostate cancer. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aac9511.","journal-title":"Sci Transl Med"},{"issue":"10","key":"3851_CR36","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/bjc.2015.128","volume":"112","author":"S Salvi","year":"2015","unstructured":"Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer [Internet]. 2015;112(10):1717\u201324. https:\/\/doi.org\/10.1038\/bjc.2015.128.","journal-title":"Br J Cancer [Internet]."},{"issue":"7","key":"3851_CR37","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol [Internet]. 2017;28(7):1508\u201316. https:\/\/doi.org\/10.1093\/annonc\/mdx155.","journal-title":"Ann Oncol [Internet]."},{"issue":"5","key":"3851_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol [Internet]. 2015;1(5):582. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1341.","journal-title":"JAMA Oncol [Internet]."},{"key":"3851_CR39","unstructured":"Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, De Santis M, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142023 update. [Internet]. 2023. ISBN 978\u201394\u201392671\u201319\u20136. Available from: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145.pdf"},{"issue":"8","key":"3851_CR40","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol [Internet]. 2015;26(8):1589\u2013604. https:\/\/doi.org\/10.1093\/annonc\/mdv257.","journal-title":"Ann Oncol [Internet]."},{"issue":"6","key":"3851_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2020.08.025","volume":"78","author":"F Saad","year":"2020","unstructured":"Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, et al. Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring. Eur Urol [Internet]. 2020;78(6):847\u201353. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.025.","journal-title":"Eur Urol [Internet]."},{"issue":"12","key":"3851_CR42","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/jco.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol [Internet]. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/jco.2015.64.2702.","journal-title":"J Clin Oncol [Internet]."},{"issue":"6","key":"3851_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urolonc.2009.11.003","volume":"29","author":"H Payne","year":"2011","unstructured":"Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol [Internet]. 2011;29(6):593\u2013601. https:\/\/doi.org\/10.1016\/j.urolonc.2009.11.003.","journal-title":"Urol Oncol [Internet]."},{"issue":"2","key":"3851_CR44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"CJ Pezaro","year":"2014","unstructured":"Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol [Internet]. 2014;65(2):270\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2013.10.055.","journal-title":"Eur Urol [Internet]."},{"issue":"16","key":"3851_CR45","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1200\/jco.2005.23.16_suppl.4682","volume":"23","author":"CH Ohlmann","year":"2005","unstructured":"Ohlmann CH, Engelmann UH, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPC) previously treated with docetaxel-based chemotherapy. J Clin Oncol [Internet]. 2005;23(16):4682\u20134682. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.4682.","journal-title":"J Clin Oncol [Internet]."},{"issue":"1","key":"3851_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol [Internet]. 2024;25(1):99\u2013107. https:\/\/doi.org\/10.1016\/s1470-2045(23)00529-6.","journal-title":"Lancet Oncol [Internet]."},{"issue":"6","key":"3851_CR47","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.ejca.2014.01.006","volume":"50","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer [Internet]. 2014;50(6):1090\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.006.","journal-title":"Eur J Cancer [Internet]."},{"issue":"1","key":"3851_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw [Internet]. 2009;7(1):99\u2013108. https:\/\/doi.org\/10.6004\/jnccn.2009.0009.","journal-title":"J Natl Compr Canc Netw [Internet]."},{"issue":"21","key":"3851_CR49","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/jco.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol [Internet]. 2007;25(21):3158\u201367. https:\/\/doi.org\/10.1200\/jco.2006.08.8823.","journal-title":"J Clin Oncol [Internet]."},{"issue":"5","key":"3851_CR50","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-015-0820-9","volume":"20","author":"M Nozawa","year":"2015","unstructured":"Nozawa M, Mukai H, Takahashi S, Uemura H, Kosaka T, Onozawa Y, et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol [Internet]. 2015;20(5):1026\u201334. https:\/\/doi.org\/10.1007\/s10147-015-0820-9.","journal-title":"Int J Clin Oncol [Internet]."},{"issue":"3","key":"3851_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2021.10.016","volume":"81","author":"G Baciarello","year":"2022","unstructured":"Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, et al. Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castration-resistant prostate cancer: the CABADOC trial. Eur Urol [Internet]. 2022;81(3):234\u201340. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.016.","journal-title":"Eur Urol [Internet]."},{"issue":"12","key":"3851_CR52","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.6004\/jnccn.2022.0063","volume":"20","author":"E Schaeffer","year":"2022","unstructured":"Schaeffer E, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines\u00ae Insights: prostate Cancer, version 1.2023: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw [Internet]. 2022;20(12):1288\u201398. https:\/\/doi.org\/10.6004\/jnccn.2022.0063.","journal-title":"J Natl Compr Canc Netw [Internet]."},{"issue":"4","key":"3851_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/nejmoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med [Internet]. 2017;377(4):352\u201360. https:\/\/doi.org\/10.1056\/nejmoa1704174.","journal-title":"N Engl J Med [Internet]."},{"issue":"2","key":"3851_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/nejmoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med [Internet]. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/nejmoa1903835.","journal-title":"N Engl J Med [Internet]."},{"key":"3851_CR55","doi-asserted-by":"publisher","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic castration-sensitive prostate cancer. N Engl J Med [Internet]. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/nejmoa1903307","DOI":"10.1056\/nejmoa1903307"},{"issue":"32","key":"3851_CR56","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/jco.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol [Internet]. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/jco.19.00799.","journal-title":"J Clin Oncol [Internet]."},{"issue":"10024","key":"3851_CR57","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet [Internet]. 2016;387(10024):1163\u201377. https:\/\/doi.org\/10.1016\/s0140-6736(15)01037-5.","journal-title":"Lancet [Internet]."},{"issue":"4","key":"3851_CR58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/nejmoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med [Internet]. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/nejmoa1702900.","journal-title":"N Engl J Med [Internet]."},{"issue":"10336","key":"3851_CR59","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/s0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet [Internet]. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/s0140-6736(22)00367-1.","journal-title":"Lancet [Internet]."},{"issue":"20","key":"3851_CR60","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/jco.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol [Internet]. 2023;41(20):3595\u2013607. https:\/\/doi.org\/10.1200\/jco.23.00041.","journal-title":"J Clin Oncol [Internet]."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03851-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03851-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:03:46Z","timestamp":1752505426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03851-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3851"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03851-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report no relationships that could be construed as a conflict of interest. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. Furthermore, no patients were involved in the design, conduct, or interpretation of our study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, no informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}